Maury Raycroft
Stock Analyst at Jefferies
(0.41)
# 3,975
Out of 4,829 analysts
54
Total ratings
17.5%
Success rate
-24.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $6.45 | +721.71% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $1.82 | +339.56% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.70 | +328.45% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.41 | +190.46% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.38 | +334.78% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $1.15 | +1,378.26% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $1.14 | +1,566.67% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $1.30 | +1,053.85% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $19.61 | +98.88% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $0.78 | +669.53% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.51 | +1,423.18% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $6.49 | +2,904.62% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $9.97 | +10.33% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $0.33 | +2,643.90% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $21.71 | -72.36% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $13.03 | +475.59% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $251.15 | -7.62% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $3.70 | +197.30% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $10.10 | +167.33% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.68 | +197.62% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $10.15 | +372.91% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.47 | +456.41% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $2.76 | +3,704.35% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $35.62 | +382.87% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $1.64 | +2,765.85% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $0.69 | +5,739.42% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.22 | +5,350.24% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.12 | +417.24% | 3 | Nov 1, 2017 |
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $6.45
Upside: +721.71%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.82
Upside: +339.56%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.70
Upside: +328.45%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.41
Upside: +190.46%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.38
Upside: +334.78%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $1.15
Upside: +1,378.26%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $1.14
Upside: +1,566.67%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $1.30
Upside: +1,053.85%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $19.61
Upside: +98.88%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.78
Upside: +669.53%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.51
Upside: +1,423.18%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $6.49
Upside: +2,904.62%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $9.97
Upside: +10.33%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.33
Upside: +2,643.90%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $21.71
Upside: -72.36%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $13.03
Upside: +475.59%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $251.15
Upside: -7.62%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $3.70
Upside: +197.30%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $10.10
Upside: +167.33%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.68
Upside: +197.62%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $10.15
Upside: +372.91%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $6.47
Upside: +456.41%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $2.76
Upside: +3,704.35%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $35.62
Upside: +382.87%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $1.64
Upside: +2,765.85%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $0.69
Upside: +5,739.42%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.22
Upside: +5,350.24%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.12
Upside: +417.24%